Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Antibody Drug Conjugates Market Growth Potential: How Will Market Size Shift Through 2030?
The antibody drug conjugates market size has experienced significant expansion in recent years. It is anticipated to increase from $16.53 billion in 2025 to $20.28 billion in 2026, registering a compound annual growth rate (CAGR) of 22.7%. This historical growth can be attributed to the rising prevalence of cancer, advancements in monoclonal antibody technology, increased adoption of targeted therapies, a surge in clinical trials for oncology drugs, and supportive regulatory environments.
The antibody drug conjugates market is anticipated to undergo significant expansion over the next few years. It is projected to achieve a valuation of $46.95 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 23.3%. This growth during the forecast period can be attributed to a heightened demand for personalized medicine, the emergence of new antibody drug conjugates with superior safety profiles, the integration of artificial intelligence in drug discovery, penetration into developing markets, and strategic alliances between biotech and pharmaceutical companies. Noteworthy trends for the upcoming period include optimizing targeted drug delivery, advancing novel linker and payload technologies, exploring combination therapies with immunotherapy, broadening the scope of oncology indications, and developing individualized cancer treatment plans.
Get A Free Sample Report With In-Depth Market Insights:
Antibody Drug Conjugates Market Demand Drivers: What’s Powering Industry Growth?
The rising volume of clinical trial studies is anticipated to drive the antibody drug conjugates market in the coming years. Clinical trials involve research investigations where volunteers participate to assess novel treatments, interventions, or tests for preventing, detecting, treating, or managing various medical conditions or diseases. Antibody-drug conjugates have become a crucial class of anti-cancer drugs, with a swift increase in the number of these conjugates progressing through clinical trials for treating solid tumors and blood-related cancers. For example, in December 2024, data from the Association of the British Pharmaceutical Industry (ABPI), a UK-based trade association, indicated a rise in the total number of industry clinical trials launched in the UK, from 411 trials in 2022 to 426 in 2023. Consequently, the growing number of clinical trial studies is fueling the antibody drug conjugates market.
Antibody Drug Conjugates Market Segment Trends And Revenue Contributors
The antibody drug conjugates market covered in this report is segmented –
1) By Type: Monoclonal Antibodies, Linker, Drug/Toxin, Other Types
2) By Product Brand: Adcertis, Kadcyla, Other Product Brands
3) By Technology: Immunogen Technology, Seattle Genetics Technology, Immunomedics Technology, Other Technology
4) By Application: Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumor, Other Applications
5) By End User: Hospital, Clinics, Other End Users
Subsegments:
1) By Monoclonal Antibodies: IgG-based Monoclonal Antibodies, IgM-based Monoclonal Antibodies, Bispecific Antibodies
2) By Linker: Cleavable Linkers, Non-cleavable Linkers, Stable Linkers
3) By Drug/Toxin: Cytotoxic Drugs, Chemotherapeutic Agents, Radioisotopes
4) By Other Types: Enzyme-Targeted ADCs, Antibody-Drug Conjugates with Immune Modulators
Antibody Drug Conjugates Market Innovation Trends: What Developments Are Reshaping The Industry?
Major companies in the antibody-drug conjugates field are introducing innovative breakthrough conjugates, such as the first single-use reactor specifically designed for manufacturing antibody drug conjugates (ADCs). This initial single-use reactor, created for producing antibody-drug conjugates (ADCs), enables faster, more flexible, and contamination-free manufacturing of these targeted cancer therapies by removing the necessity for cleaning and sterilization between batches. For instance, in September 2024, Merck & Co., Inc., a US-based pharmaceutical company, unveiled the Mobius ADC reactor. To satisfy the increasing demand for more efficient and safer manufacturing processes for antibody-drug conjugates (ADCs), this inventive reactor addresses the unique challenges of ADC production, delivering a 70% boost in efficiency while substantially decreasing the dangers of cross-contamination and the laborious cleaning demanded by traditional stainless steel or glass reactors. The Mobius ADC Reactor incorporates Ultimus Film technology, improving bag strength, durability, and leak resistance to ensure excellent product quality.
Antibody Drug Conjugates Market Competitive Landscape: Which Companies Lead The Industry?
Major companies operating in the antibody drug conjugates market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Millennium Pharmaceuticals Inc., Gilead Sciences Inc., Daiichi Sankyo Company Limited, Sorrento Therapeutics Inc., Astellas Pharma Inc., Seagen Inc., Synthon BV, Genentech Inc., ImmunoGen Inc., Nordic Nanovector ASA, ADC Therapeutics SA, Immunomedics Inc., Mersana Therapeutics Inc., Heidelberg Pharma AG, Celldex Therapeutics Inc., Oxford BioTherapeutics, Concortis Biotherapeutics Corp., Antikor BioPharma Ltd., Eisai Co. Ltd., Merck KGaA
View The Full Antibody Drug Conjugates Market Report:
Antibody Drug Conjugates Market Geographic Landscape: Which Region Dominates Industry Growth?
North America was the largest region in the antibody-drug conjugates (ADCs) market in 2025. The Middle East is expected to be the fastest-growing region in the global antibody drug conjugates market share during the forecast period. The regions covered in the antibody drug conjugates market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model